GLIPIZIDE AND METFORMIN HCL

GLIPIZIDE AND METFORMIN HCL was reported 70 times

GLIPIZIDE AND METFORMIN HCL is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 VENOUS HAEMORRHAGE 1 0.0032
1 ELECTROCARDIOGRAM T WAVE PEAKED 1 0.0025
2 PERINEAL PAIN 1 0.0014
3 PARASOMNIA 1 0.0014
4 LYMPHADENECTOMY 1 0.0010
5 VAGINAL ODOUR 1 0.0008
6 INFUSION SITE IRRITATION 1 0.0008
7 CARDIOACTIVE DRUG LEVEL INCREASED 1 0.0008
8 VULVOVAGINAL CANDIDIASIS 1 0.0007
9 SEBORRHOEIC DERMATITIS 1 0.0006
10 ESSENTIAL HYPERTENSION 1 0.0005
11 INFUSION SITE INFECTION 1 0.0004
12 INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS 2 0.0004
13 ANXIETY DISORDER 1 0.0003
14 FAECES SOFT 2 0.0003
15 VULVOVAGINAL DISCOMFORT 1 0.0002
16 SKIN ABRASION 1 0.0002
17 VULVOVAGINAL PAIN 1 0.0002
18 HEPATIC ENZYME ABNORMAL 1 0.0002
19 VEIN DISORDER 1 0.0002
20 TOE AMPUTATION 1 0.0002
21 INCREASED UPPER AIRWAY SECRETION 1 0.0002
22 FEELING OF BODY TEMPERATURE CHANGE 1 0.0002
23 SOMNAMBULISM 1 0.0002
24 CROHN'S DISEASE 1 0.0001
25 BLINDNESS TRANSIENT 1 0.0001
26 ACIDOSIS 1 0.0001
27 PRODUCT ADMINISTRATION INTERRUPTED 1 0.0001
28 HICCUPS 1 0.0001
29 GLYCOSYLATED HAEMOGLOBIN INCREASED 3 0.0001
30 SKIN SWELLING 1 0.0001
31 VAGINAL DISCHARGE 1 0.0001
32 DRY THROAT 1 0.0001
33 EUPHORIC MOOD 1 0.0001
34 TRANSFUSION 1 0.0001
35 INTRAOCULAR PRESSURE INCREASED 1 0.0001
36 HYPOPHAGIA 2 0.0001
37 INFUSION SITE PAIN 1 0.0001
38 HAIR TEXTURE ABNORMAL 1 0.0001
39 FREQUENT BOWEL MOVEMENTS 2 0.0001
40 BLINDNESS UNILATERAL 1 0.0001
41 HAEMORRHAGE INTRACRANIAL 1 0.0001
42 BONE LOSS 1 0.0001
43 ECONOMIC PROBLEM 1 0.0001
44 MULTIPLE FRACTURES 1 0.0001
45 UPPER GASTROINTESTINAL HAEMORRHAGE 1 0.0001
46 HYPERKALAEMIA 2 0.0001
47 THIRST 1 0.0001
48 PRODUCT PHYSICAL ISSUE 1 0.0000
49 RIB FRACTURE 1 0.0000
50 TOOTH LOSS 1 0.0000
51 RETCHING 1 0.0000
52 PANCREATITIS ACUTE 1 0.0000
53 HYPOGLYCAEMIA 2 0.0000
54 FIBROMYALGIA 1 0.0000
55 ABDOMINAL PAIN LOWER 1 0.0000
56 HEPATITIS 1 0.0000
57 EXPOSURE VIA SKIN CONTACT 1 0.0000
58 ANHEDONIA 1 0.0000
59 MENTAL STATUS CHANGES 1 0.0000
60 WOUND 1 0.0000
61 LACRIMATION INCREASED 1 0.0000
62 INJECTION SITE RASH 1 0.0000
63 BONE DENSITY DECREASED 1 0.0000
64 OSTEONECROSIS 1 0.0000
65 STAPHYLOCOCCAL INFECTION 1 0.0000
66 TYPE 2 DIABETES MELLITUS 1 0.0000
67 NEOPLASM PROGRESSION 1 0.0000
68 HEART RATE DECREASED 1 0.0000
69 MYELOSUPPRESSION 1 0.0000
70 DYSURIA 1 0.0000
71 EYE SWELLING 1 0.0000
72 INTESTINAL OBSTRUCTION 1 0.0000
73 CHRONIC KIDNEY DISEASE 2 0.0000
74 WHITE BLOOD CELL COUNT INCREASED 1 0.0000
75 DISORIENTATION 1 0.0000
76 OSTEOPOROSIS 1 0.0000
77 TREATMENT FAILURE 2 0.0000
78 COMPLETED SUICIDE 2 0.0000
79 POLLAKIURIA 1 0.0000
80 CARDIO-RESPIRATORY ARREST 1 0.0000
81 OSTEOARTHRITIS 1 0.0000
82 RENAL FAILURE ACUTE 1 0.0000
83 SEPTIC SHOCK 1 0.0000
84 LIVER DISORDER 1 0.0000
85 BLOOD GLUCOSE INCREASED 4 0.0000
86 ARRHYTHMIA 1 0.0000
87 OCULAR HYPERAEMIA 1 0.0000
88 BLOOD GLUCOSE DECREASED 1 0.0000
89 THERAPY CESSATION 1 0.0000
90 ILLNESS 2 0.0000
91 INFLAMMATION 1 0.0000
92 ECZEMA 1 0.0000
93 HAEMATOCHEZIA 1 0.0000
94 NECK PAIN 1 0.0000
95 ABDOMINAL DISCOMFORT 3 0.0000
96 FLATULENCE 1 0.0000
97 DYSPHONIA 1 0.0000
98 BONE PAIN 1 0.0000
99 NASAL CONGESTION 1 0.0000
100 PRODUCT USE ISSUE 3 0.0000
101 PRODUCT DOSE OMISSION 1 0.0000
102 NEOPLASM MALIGNANT 1 0.0000
103 ABDOMINAL PAIN UPPER 3 0.0000
104 INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION 1 0.0000
105 INFECTION 2 0.0000
106 RESPIRATORY FAILURE 1 0.0000
107 HALLUCINATION 1 0.0000
108 HOT FLUSH 1 0.0000
109 PERIPHERAL SWELLING 2 0.0000
110 ARTHRITIS 1 0.0000
111 PARAESTHESIA 2 0.0000
112 GASTROOESOPHAGEAL REFLUX DISEASE 1 0.0000
113 FALL 4 0.0000
114 RENAL IMPAIRMENT 1 0.0000
115 TOXICITY TO VARIOUS AGENTS 2 0.0000
116 SKIN EXFOLIATION 1 0.0000
117 PRODUCT STORAGE ERROR 1 0.0000
118 INTENTIONAL PRODUCT MISUSE 1 0.0000
119 MUSCULOSKELETAL STIFFNESS 1 0.0000
120 NEUROPATHY PERIPHERAL 1 0.0000
121 CONTUSION 1 0.0000
122 DIZZINESS 5 0.0000
123 FLUSHING 1 0.0000
124 CHEST DISCOMFORT 1 0.0000
125 MALIGNANT NEOPLASM PROGRESSION 1 0.0000
126 ACCIDENTAL EXPOSURE TO PRODUCT 1 0.0000
127 PLATELET COUNT DECREASED 1 0.0000
128 SEPSIS 1 0.0000
129 DECREASED APPETITE 2 0.0000
130 CHILLS 1 0.0000
131 FEELING ABNORMAL 2 0.0000
132 JOINT SWELLING 1 0.0000
133 EMOTIONAL DISTRESS 1 0.0000
134 VISUAL IMPAIRMENT 1 0.0000
135 PRURITUS 3 0.0000
136 LOSS OF CONSCIOUSNESS 1 0.0000
137 HYPERHIDROSIS 1 0.0000
138 PSORIASIS 1 0.0000
139 RENAL FAILURE 1 0.0000
140 DRY SKIN 1 0.0000
141 VISION BLURRED 1 0.0000
142 HOSPITALISATION 1 0.0000
143 PNEUMONIA 2 0.0000
144 TREMOR 1 0.0000
145 MYOCARDIAL INFARCTION 1 0.0000
146 COVID-19 1 0.0000
147 NASOPHARYNGITIS 1 0.0000
148 ASTHENIA 2 0.0000
149 FATIGUE 4 0.0000
150 ERYTHEMA 1 0.0000
151 HEADACHE 3 0.0000
152 DIARRHOEA 3 0.0000
153 OVERDOSE 1 0.0000
154 RASH 2 0.0000
155 DEPRESSION 1 0.0000
156 INCORRECT DOSE ADMINISTERED 1 0.0000
157 ABDOMINAL PAIN 1 0.0000
158 PRODUCT USE IN UNAPPROVED INDICATION 1 0.0000
159 DRUG INEFFECTIVE 5 0.0000
160 COUGH 1 0.0000
161 DYSPNOEA 2 0.0000
162 ANXIETY 1 0.0000
163 PRODUCT DOSE OMISSION ISSUE 1 0.0000
164 PAIN IN EXTREMITY 1 0.0000
165 INJECTION SITE PAIN 1 0.0000
166 PAIN 2 0.0000
167 NAUSEA 2 0.0000
168 ARTHRALGIA 1 0.0000
169 VOMITING 1 0.0000
170 OFF LABEL USE 1 0.0000